BiotechTube

duloxetine HCl

ApprovedCompleted
0 watching 0 views this week🔥 Hot
85
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Stress Urinary Incontinence

Conditions

Stress Urinary Incontinence

Trial Timeline

Feb 1, 2004 → Jul 1, 2005

NCT ID
NCT00190905

About duloxetine HCl

duloxetine HCl is a approved stage product being developed by Eli Lilly for Stress Urinary Incontinence. The current trial status is completed. This product is registered under clinical trial identifier NCT00190905. Target conditions include Stress Urinary Incontinence.

Hype Score Breakdown

Clinical
30
Activity
20
Company
10
Novelty
10
Community
12

Clinical Trials (1)

NCT IDPhaseStatus
NCT00190905ApprovedCompleted

Competing Products

20 competing products in Stress Urinary Incontinence

See all competitors
ProductCompanyStageHype Score
Duloxetine + placeboEli LillyPhase 2
52
agenT-797MiNK TherapeuticsPhase 1
25
Thermal stress and performance without a pre-cooling protocolPetros PharmaceuticalsPre-clinical
15
solifenacinAstellas PharmaApproved
85
SivelestatEli LillyPhase 1/2
41
Duloxetine + PlaceboEli LillyPhase 3
77
DuloxetineEli LillyPhase 3
77
Duloxetine + PlaceboEli LillyPhase 3
77
DuloxetineEli LillyPhase 3
77
Duloxetine hydrochlorideEli LillyPhase 3
77
DuloxetineEli LillyPhase 3
77
duloxetine + PlaceboEli LillyPhase 2
52
Exenatide + InsulinEli LillyPhase 2/3
65
DuloxetineEli LillyPhase 3
77
Orforglipron + PlaceboEli LillyPhase 3
77
Duloxetine hydrochloride + placeboEli LillyApproved
85
Duloxetine + PlaceboEli LillyPhase 3
77
duloxetine + placeboEli LillyPhase 3
77
DuloxetineEli LillyPhase 3
77
Duloxetine Hydrochloride + placeboEli LillyPhase 3
77

Other Products from Eli Lilly

Insulin Glargine + Insulin Lispro Premix (mid-mixture and low-mixture)Approved
85
Olanzapine + PlaceboApproved
85
exenatide and sitagliptin + exenatide and placeboApproved
85
Tirzepatide + PlaceboApproved
85
tadalafilApproved
85